A phase 2 study of dasatinib-combined chemotherapy in patients with relapsed Philadelphia chromosome-positive acute lymphoid leukemia.

A phase 2 study of dasatinib-combined chemotherapy in patients with relapsed Philadelphia chromosome-positive acute lymphoid leukemia. - A phase 2 study of dasatinib-combined chemotherapy in patients with relapsed Philadelphia chromosome-positive acute lymphoid leukemia.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005352

Enrollment

Registered

2011-04-01

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Philadelphia chromosome positive acute lymphoblastic leukemia

Interventions

Dasatinib combined chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Relapsed Ph-chromosome positive acute lymphoblastic leukemia. 2. PS 0-2 (ECOG) 3. Adequate hepatic, renal, pulmonary and cardiac function 4. No active gastro-intestinal bleeding 5. No evidence of CNS relapse 6. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Severe comorbidity (infection, lung disease, hypertension, heart failure, diabetes mellitus) 2. Recent history of ischemic heart disease 3. Other active neoplasms 4. Pregnant and/or lactating woman 5. Psychological disorders 6. Positive HBs antigen and/or anti-HIV antibody 7. Received allogeneic stem cell transplantation within 100 days 8. Receiving immunosuppressive agents (cyclosporine, tacrolimus)

Design outcomes

Primary

Measure	Time frame
Complete hematological remission rate in induction therapy	—

Secondary

Measure	Time frame
Hematological remission rate Complete cytogenetical remission rate Major molecular remission rate Overall survival rate at 1 year Treatment related toxicity	—

Countries

Japan

Contacts

Public ContactShuichi Mizuta

Fujita Health University Department of Hematology

mizuta@mb.ccnw.ne.jp0562-93-9243

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026